Oragenics, Inc. Announces One-for-Thirty Reverse Stock Split

SARASOTA, Fla., May 28, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a biotech company advancing innovative treatments for brain-related health conditions, today announced that its Board of Directors (the "Board") on May 27, 2025 approved a One-for- Thirty (1-for-30) reverse stock split of the Company's issued and outstanding shares of common stock, par value $0.001 per share (the "Reverse Stock Split"). As a result of the Reverse Stock Split, the Company's ...